Biotech | April 25, 2022
Shilpa Medicare receives NoC for biosimilar Aflibercept
Aflibercept is the second biosimilar product that has entered the clinical trial phase after biosimilar Adalimumab
Aflibercept is the second biosimilar product that has entered the clinical trial phase after biosimilar Adalimumab
The Phase 3 trial will be conducted under the auspices of the first Regenerative Medicine Advanced Therapy (RMAT) designation approved by the USFDA for an EV therapeutic
Support for biologics manufacturability and Industry 4.0 initiatives
Marks the second of three biosimilars Amneal expects to receive U.S. approval for in 2022
An RMAT confers eligibility for accelerated approval and priority review of biologics licensing applications (BLA)
Pharmapack trends are a key barometer of global device and packing opportunities in 2022
Makrolon polycarbonate is key to needle-free injections that can stand up to sterilization
MilliporeSigma to become the first company to offer a fully integrated ecosystem for advanced process technologies
New high-throughput, no-wash assays contribute to the development, manufacture and quality control of safer, more effective biotherapeutics
CanSinoBIO will continue to focus on developing a variety of innovative preventive vaccines in its diversified product pipeline with proprietary technologies, including the inhaled version of its COVID-19 vaccine, Convidecia
Subscribe To Our Newsletter & Stay Updated
